首页 > 最新文献

Israel Medical Association Journal最新文献

英文 中文
Term Breech Presentation and Timing of Delivery. 临产阵痛和分娩时间。
IF 1.8 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-10-01
Noa Leybovitz-Haleluya, Alla Saban, Adi Yariv, Reli Hershkovitz

Background: Breech presentation is a major indication for cesarean delivery (CD); however, the ideal timing of breech CD is debatable.

Objectives: To study the influence of gestational age at the time of CD in breech presentation on maternal and fetal complications.

Methods: We conducted a retrospective study including term singleton CDs of breech presentation between February 2020 and January 2022 at a tertiary medical center. Maternal and neonatal outcomes were compared by gestational age at the time of CD. Logistic regression models were constructed to adjust for confounders.

Results: The study population included 468 CDs, 227 (48.5%) were at 37 + 0 to 38 + 6 weeks, 168 (36%) were at 39 + 0 to 39 + 6 weeks (comparison group), and 73 (15.5%) were at ≥ 40 weeks at the time of delivery. The rate of emergent CDs was significantly higher in both study groups. The composite of maternal adverse outcomes was also significantly higher at ≥ 40 weeks of gestation. Using logistic regression model, associations remained significant. The adjusted odds ratios (OR) for emergent CDs at 37 + 0 to 38 + 6 weeks and at ≥ 40 weeks were 1.65 (P = 0.018) and 2.407 (P = 0.004), respectively. Adjusted OR for maternal adverse outcomes at ≥ 40 weeks was 2.094 (P = 0.018). Higher rates of emergent CDs in both study groups compared to the comparison group was noted. A composite of maternal adverse outcomes was significantly higher at ≥ 40 weeks of gestation. This association remained significant after controlling for potential confounders.

Conclusions: CDs at 39 + 0 to 39 + 6 weeks are associated with better maternal outcomes and lower rates of emergent CDs.

背景:臀先露是剖宫产(CD)的主要指征;然而,臀先露剖宫产的理想时机尚存争议:研究臀位分娩时的胎龄对母体和胎儿并发症的影响:我们在一家三级医疗中心开展了一项回顾性研究,研究对象包括 2020 年 2 月至 2022 年 1 月间臀先露的足月单胎分娩。产妇和新生儿的预后按臀先露时的胎龄进行比较。建立逻辑回归模型以调整混杂因素:研究对象包括 468 例 CD,其中 227 例(48.5%)在 37+0 至 38+6 周分娩,168 例(36%)在 39+0 至 39+6 周分娩(对比组),73 例(15.5%)在≥40 周分娩。两个研究组的急诊分娩率都明显较高。妊娠≥40周的孕产妇不良后果综合指数也明显较高。使用逻辑回归模型,相关性仍然很明显。妊娠 37+0 至 38+6 周和妊娠≥40 周时发生急诊 CD 的调整赔率(OR)分别为 1.65(P = 0.018)和 2.407(P = 0.004)。≥40周时产妇不良结局的调整OR值为2.094(P = 0.018)。与对比组相比,两个研究组的急诊 CD 发生率均较高。妊娠≥40周时,孕产妇不良结局的综合指数明显更高。在控制了潜在的混杂因素后,这种关联仍然很明显:结论:妊娠 39+0 到 39+6 周时进行产前诊断与更好的产妇预后和更低的急诊产前诊断率有关。
{"title":"Term Breech Presentation and Timing of Delivery.","authors":"Noa Leybovitz-Haleluya, Alla Saban, Adi Yariv, Reli Hershkovitz","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Breech presentation is a major indication for cesarean delivery (CD); however, the ideal timing of breech CD is debatable.</p><p><strong>Objectives: </strong>To study the influence of gestational age at the time of CD in breech presentation on maternal and fetal complications.</p><p><strong>Methods: </strong>We conducted a retrospective study including term singleton CDs of breech presentation between February 2020 and January 2022 at a tertiary medical center. Maternal and neonatal outcomes were compared by gestational age at the time of CD. Logistic regression models were constructed to adjust for confounders.</p><p><strong>Results: </strong>The study population included 468 CDs, 227 (48.5%) were at 37 + 0 to 38 + 6 weeks, 168 (36%) were at 39 + 0 to 39 + 6 weeks (comparison group), and 73 (15.5%) were at ≥ 40 weeks at the time of delivery. The rate of emergent CDs was significantly higher in both study groups. The composite of maternal adverse outcomes was also significantly higher at ≥ 40 weeks of gestation. Using logistic regression model, associations remained significant. The adjusted odds ratios (OR) for emergent CDs at 37 + 0 to 38 + 6 weeks and at ≥ 40 weeks were 1.65 (P = 0.018) and 2.407 (P = 0.004), respectively. Adjusted OR for maternal adverse outcomes at ≥ 40 weeks was 2.094 (P = 0.018). Higher rates of emergent CDs in both study groups compared to the comparison group was noted. A composite of maternal adverse outcomes was significantly higher at ≥ 40 weeks of gestation. This association remained significant after controlling for potential confounders.</p><p><strong>Conclusions: </strong>CDs at 39 + 0 to 39 + 6 weeks are associated with better maternal outcomes and lower rates of emergent CDs.</p>","PeriodicalId":50268,"journal":{"name":"Israel Medical Association Journal","volume":"26 9","pages":"555-559"},"PeriodicalIF":1.8,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142479624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Introduction of a New Toxicology Consult Service in a Large Tertiary Care Teaching Hospital. 在一家大型三级教学医院引入新的毒理学咨询服务。
IF 1.8 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-10-01
Or Segev, Christopher Hoyte, Nicole Taylor, Amanda Katz, Dennis Scolnik, Efrat Zandberg, Eyal Hassoun, Miguel Glatstein

Background: Clinical toxicology is not a certified specialty in Israel, consequently there are a limited number of toxicologists and toxicology services available for consultation.

Objectives: To establish a medical toxicology consultation service focusing on bedside consultations, which had not previously been available in Israel.

Methods: This single-center, retrospective chart review of toxicology consults was conducted during the first years after the initiation of a new toxicology service.

Results: From September 2017 to December 2021, 1703 toxicology consultations were conducted. The most common exposures and reasons for consultation included psychotropic medications (427, 23%), analgesics and anti-inflammatory medications (353, 19%), household products (312, 17%), substances of abuse (240, 13%), and natural toxins (142, 8%). Bedside medical toxicology consultations were performed in 1036 cases (62%) during daytime and night shifts. The number of consultation requests increased steadily over the study period.

Conclusions: The new toxicology service led to a significant change in the institution's approach to toxicological patients. A bedside toxicology service could help reduce the healthcare burden on national poison centers and can offer readily available, personalized, medical toxicology care.

背景:在以色列,临床毒理学并不是一个经过认证的专业:在以色列,临床毒理学并不是一个经过认证的专业,因此可提供咨询的毒理学专家和毒理学服务数量有限:目的:建立以床旁会诊为重点的医学毒理学咨询服务,这在以色列以前是没有的:方法:在启动新的毒理学服务后的最初几年,对毒理学会诊进行单中心、回顾性病历审查:从 2017 年 9 月到 2021 年 12 月,共进行了 1703 次毒理学会诊。最常见的接触和就诊原因包括精神药物(427例,23%)、镇痛药和消炎药(353例,19%)、家用产品(312例,17%)、滥用药物(240例,13%)和天然毒素(142例,8%)。在日班和夜班期间,共为 1036 例(62%)患者进行了床边医学毒理学会诊。在研究期间,咨询请求的数量稳步增长:结论:新的毒理学服务极大地改变了医院对毒理学病人的处理方式。床旁毒理学服务有助于减轻国家毒物中心的医疗负担,并能提供随时可用的个性化医疗毒理学护理。
{"title":"Introduction of a New Toxicology Consult Service in a Large Tertiary Care Teaching Hospital.","authors":"Or Segev, Christopher Hoyte, Nicole Taylor, Amanda Katz, Dennis Scolnik, Efrat Zandberg, Eyal Hassoun, Miguel Glatstein","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Clinical toxicology is not a certified specialty in Israel, consequently there are a limited number of toxicologists and toxicology services available for consultation.</p><p><strong>Objectives: </strong>To establish a medical toxicology consultation service focusing on bedside consultations, which had not previously been available in Israel.</p><p><strong>Methods: </strong>This single-center, retrospective chart review of toxicology consults was conducted during the first years after the initiation of a new toxicology service.</p><p><strong>Results: </strong>From September 2017 to December 2021, 1703 toxicology consultations were conducted. The most common exposures and reasons for consultation included psychotropic medications (427, 23%), analgesics and anti-inflammatory medications (353, 19%), household products (312, 17%), substances of abuse (240, 13%), and natural toxins (142, 8%). Bedside medical toxicology consultations were performed in 1036 cases (62%) during daytime and night shifts. The number of consultation requests increased steadily over the study period.</p><p><strong>Conclusions: </strong>The new toxicology service led to a significant change in the institution's approach to toxicological patients. A bedside toxicology service could help reduce the healthcare burden on national poison centers and can offer readily available, personalized, medical toxicology care.</p>","PeriodicalId":50268,"journal":{"name":"Israel Medical Association Journal","volume":"26 9","pages":"572-576"},"PeriodicalIF":1.8,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142479620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of Vitamin K Antagonists Management and Control in Patients with Mechanical Prosthetic Heart Valves during the COVID-19 Pandemic. 评估 COVID-19 大流行期间机械人工心脏瓣膜患者的维生素 K 拮抗剂管理和控制情况。
IF 1.8 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-10-01
Ilana Gilboa, Keren Rodrig, Tzipi Hornik-Lurie, David Pereg

Background: Patients with mechanical prosthetic heart valves must be treated with vitamin K antagonists (VKA) due to an increased risk of valve thrombosis and systemic embolism.

Objectives: To assess the effects of the COVID-19 pandemic on VKA treatment control in patients with mechanical prosthetic heart valves.

Methods: We conducted a retrospective nationwide cohort study using the Clalit Health Services database. The cohort included patients who underwent either aortic or mitral valve replacement using a prosthetic mechanical valve. The primary outcomes included the overall time in therapeutic range (TTR) and the percent of patients with a TTR < 50% during the first year of the COVID-19 pandemic compared to preceding year.

Results: The cohort included 2381 patients. The percentage of patients who had at least two international normalized ratio (INR) tests during the first year of the COVID-19 pandemic was significantly lower compared to the year preceding the pandemic (81% and 87%, respectively, P < 0.001). In both years, the percentage of patients without any documented INR test was high (31.5% in the first COVID-19 pandemic year and 28.9% in the preceding year, P < 0.001). TTR was significantly lower during the 1st year of the COVID-19 pandemic compared to the preceding year (68.1% ± 26 and 69.4% ± 24, P = 0.03). A TTR > 50% was demonstrated in 78% and 81% during the pandemic and the preceding year, P = 0.009.

Conclusions: We noted overall poor VKA control in patients with mechanical heart valves. During the COVID-19 pandemic, VKA control became even worse as reflected by significantly lower TTR and INR tests rates.

背景:由于瓣膜血栓形成和全身性栓塞的风险增加,机械性人工心脏瓣膜患者必须使用维生素K拮抗剂(VKA)治疗:评估 COVID-19 大流行对机械人工心脏瓣膜患者 VKA 治疗控制的影响:我们利用 Clalit 健康服务数据库开展了一项全国性回顾性队列研究。研究对象包括使用人工机械瓣膜接受主动脉瓣或二尖瓣置换术的患者。主要结果包括治疗范围内的总时间(TTR)和 COVID-19 大流行第一年与前一年相比 TTR < 50% 的患者百分比:结果:队列中有 2381 名患者。在COVID-19大流行的第一年,至少进行过两次国际标准化比值(INR)检测的患者比例明显低于大流行前一年(分别为81%和87%,P<0.001)。在这两年中,没有任何 INR 检测记录的患者比例都很高(COVID-19 大流行第一年为 31.5%,前一年为 28.9%,P<0.001)。与前一年相比,COVID-19 大流行第一年的 TTR 明显降低(68.1% ± 26 和 69.4% ± 24,P = 0.03)。大流行期间和前一年分别有 78% 和 81% 的患者 TTR >50%,P = 0.009:我们注意到,机械心脏瓣膜患者的 VKA 控制率总体较低。在 COVID-19 大流行期间,VKA 控制更差,这反映在 TTR 和 INR 检测率显著降低。
{"title":"Evaluation of Vitamin K Antagonists Management and Control in Patients with Mechanical Prosthetic Heart Valves during the COVID-19 Pandemic.","authors":"Ilana Gilboa, Keren Rodrig, Tzipi Hornik-Lurie, David Pereg","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Patients with mechanical prosthetic heart valves must be treated with vitamin K antagonists (VKA) due to an increased risk of valve thrombosis and systemic embolism.</p><p><strong>Objectives: </strong>To assess the effects of the COVID-19 pandemic on VKA treatment control in patients with mechanical prosthetic heart valves.</p><p><strong>Methods: </strong>We conducted a retrospective nationwide cohort study using the Clalit Health Services database. The cohort included patients who underwent either aortic or mitral valve replacement using a prosthetic mechanical valve. The primary outcomes included the overall time in therapeutic range (TTR) and the percent of patients with a TTR < 50% during the first year of the COVID-19 pandemic compared to preceding year.</p><p><strong>Results: </strong>The cohort included 2381 patients. The percentage of patients who had at least two international normalized ratio (INR) tests during the first year of the COVID-19 pandemic was significantly lower compared to the year preceding the pandemic (81% and 87%, respectively, P < 0.001). In both years, the percentage of patients without any documented INR test was high (31.5% in the first COVID-19 pandemic year and 28.9% in the preceding year, P < 0.001). TTR was significantly lower during the 1st year of the COVID-19 pandemic compared to the preceding year (68.1% ± 26 and 69.4% ± 24, P = 0.03). A TTR > 50% was demonstrated in 78% and 81% during the pandemic and the preceding year, P = 0.009.</p><p><strong>Conclusions: </strong>We noted overall poor VKA control in patients with mechanical heart valves. During the COVID-19 pandemic, VKA control became even worse as reflected by significantly lower TTR and INR tests rates.</p>","PeriodicalId":50268,"journal":{"name":"Israel Medical Association Journal","volume":"26 9","pages":"546-550"},"PeriodicalIF":1.8,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142479616","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Association Between Serum Ferritin Levels and Main Systemic Sclerosis Features: A Retrospective Study from a Tertiary Center. 血清铁蛋白水平与系统性硬化症主要特征之间的关系:来自一家三级医疗中心的回顾性研究
IF 1.8 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-10-01
Shirley Markovich Sholomon, Sami Giryes, Vika Shataylo, Yolanda Braun-Moscovici, Alexandra Balbir-Gurman

Background: Serum ferritin is a sensitive inflammatory biomarker reflecting cell damage and oxidative stress in inflammatory rheumatic diseases. The use of ferritin for assessment of systemic sclerosis (SSc) activity, severity, and prognosis has not been fully elucidated.

Objectives: To assess the correlation between serum ferritin levels and SSc disease parameters, complications, and outcome.

Methods: Demographic, clinical, and laboratory data, including blood levels of ferritin, were collected from files of patients with SSc who were treated at the Rheumatology Institute at Rambam Health Care Campus from January 2004 to July 2021. The study compared SSc patients with elevated levels of ferritin to those with normal levels.

Results: We extracted data of 241 SSc patients (80% female, 60% with diffuse SSc, mean age 54 ± 15.4 years, mean disease duration 6.8 ± 4.5 years). During follow-up, 39% died. Elevated ferritin levels positively correlated with male sex; short disease duration; lung, heart, and kidney involvement; higher modified Rodnan skin score; anemia; elevated levels of creatinine kinase, C-reactive protein, creatinine, and troponin; reduced pulmonary function tests (forced vital capacity and diffusion capacity of the lung for carbon monoxide); and left ventricular ejection fraction. There were no correlations between ferritin levels and pulmonary hypertension or gastrointestinal involvement. Levels of ferritin negatively correlated with anti-centromere antibodies.

Conclusions: In SSc, ferritin can serve as a marker for ongoing systemic inflammation and prognosis, particularly in patients with lung and heart involvement. Further studies on serial ferritin measurement in the management of SSc patients are warranted.

背景:血清铁蛋白是一种敏感的炎症生物标志物,可反映炎症性风湿病中的细胞损伤和氧化应激。使用铁蛋白评估系统性硬化症(SSc)的活动性、严重程度和预后尚未完全阐明:评估血清铁蛋白水平与 SSc 疾病参数、并发症和预后之间的相关性:方法:从 2004 年 1 月至 2021 年 7 月在兰巴姆医疗保健园区风湿病研究所接受治疗的 SSc 患者档案中收集人口统计学、临床和实验室数据,包括血液中的铁蛋白水平。研究将铁蛋白水平升高的 SSc 患者与铁蛋白水平正常的患者进行了比较:我们提取了 241 名 SSc 患者(80% 为女性,60% 为弥漫性 SSc 患者,平均年龄为 54 ± 15.4 岁,平均病程为 6.8 ± 4.5 年)的数据。在随访期间,39%的患者死亡。铁蛋白水平升高与以下因素呈正相关:男性;病程短;肺、心脏和肾脏受累;改良罗德南皮肤评分较高;贫血;肌酸激酶、C 反应蛋白、肌酐和肌钙蛋白水平升高;肺功能测试(强迫生命容量和肺对一氧化碳的弥散容量)降低;左心室射血分数降低。铁蛋白水平与肺动脉高压或胃肠道受累之间没有相关性。铁蛋白水平与抗中心粒抗体呈负相关:结论:在 SSc 患者中,铁蛋白可作为持续全身炎症和预后的标志物,尤其是在肺部和心脏受累的患者中。在治疗 SSc 患者的过程中,有必要对连续测量铁蛋白进行进一步研究。
{"title":"The Association Between Serum Ferritin Levels and Main Systemic Sclerosis Features: A Retrospective Study from a Tertiary Center.","authors":"Shirley Markovich Sholomon, Sami Giryes, Vika Shataylo, Yolanda Braun-Moscovici, Alexandra Balbir-Gurman","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Serum ferritin is a sensitive inflammatory biomarker reflecting cell damage and oxidative stress in inflammatory rheumatic diseases. The use of ferritin for assessment of systemic sclerosis (SSc) activity, severity, and prognosis has not been fully elucidated.</p><p><strong>Objectives: </strong>To assess the correlation between serum ferritin levels and SSc disease parameters, complications, and outcome.</p><p><strong>Methods: </strong>Demographic, clinical, and laboratory data, including blood levels of ferritin, were collected from files of patients with SSc who were treated at the Rheumatology Institute at Rambam Health Care Campus from January 2004 to July 2021. The study compared SSc patients with elevated levels of ferritin to those with normal levels.</p><p><strong>Results: </strong>We extracted data of 241 SSc patients (80% female, 60% with diffuse SSc, mean age 54 ± 15.4 years, mean disease duration 6.8 ± 4.5 years). During follow-up, 39% died. Elevated ferritin levels positively correlated with male sex; short disease duration; lung, heart, and kidney involvement; higher modified Rodnan skin score; anemia; elevated levels of creatinine kinase, C-reactive protein, creatinine, and troponin; reduced pulmonary function tests (forced vital capacity and diffusion capacity of the lung for carbon monoxide); and left ventricular ejection fraction. There were no correlations between ferritin levels and pulmonary hypertension or gastrointestinal involvement. Levels of ferritin negatively correlated with anti-centromere antibodies.</p><p><strong>Conclusions: </strong>In SSc, ferritin can serve as a marker for ongoing systemic inflammation and prognosis, particularly in patients with lung and heart involvement. Further studies on serial ferritin measurement in the management of SSc patients are warranted.</p>","PeriodicalId":50268,"journal":{"name":"Israel Medical Association Journal","volume":"26 9","pages":"583-588"},"PeriodicalIF":1.8,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142479625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Novel CLCN1 Gene Mutation Associated with Hypokalemic Periodic Paralysis in a Pregnant Woman. 与一名孕妇低钾血症性周期性麻痹有关的新型 CLCN1 基因突变
IF 1.8 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-10-01
Jawad Atrash, Omar Abu Libdeh, Bashar Fteiha, Marwan Abu Sneineh, Alon Bnaya, Linda Shavit
{"title":"A Novel CLCN1 Gene Mutation Associated with Hypokalemic Periodic Paralysis in a Pregnant Woman.","authors":"Jawad Atrash, Omar Abu Libdeh, Bashar Fteiha, Marwan Abu Sneineh, Alon Bnaya, Linda Shavit","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":50268,"journal":{"name":"Israel Medical Association Journal","volume":"26 9","pages":"591-592"},"PeriodicalIF":1.8,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142479613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Introducing Cloacagram in Israel: Advancing Anatomical Assessment and Surgical Planning for Cloacal Malformations. 在以色列引入 Cloacagram:推进泄殖腔畸形的解剖评估和手术规划。
IF 1.8 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-10-01
Maya Paran, Osnat Konen, Tal May, Moussa Totah, Michael Levinson, Michael Segal, Dragan Kravarusic, Inbal Samuk

Background: Cloacal malformation represents the rarest and most complex congenital anorectal malformation in females and is characterized by the convergence of urinary, gynecological, and intestinal systems within a single common channel. Three-dimensional computed tomography reconstruction (3D CT cloacagram) has emerged as a valuable method for anatomical assessment and preoperative planning.

Objectives: To evaluate our experience with 3D CT cloacagram and assess its results.

Methods: This retrospective case series included all patients with cloacal malformation who underwent preoperative 3D CT cloacagram at a single institution during 2019-2023. Collected data included patient characteristics, timing of the 3D CT cloacagram, results of the 3D CT cloacagram, comparison with endoscopic results, surgical procedures, and postoperative outcome.

Results: Six patients with cloacal malformation were included in this study, including two with posterior cloaca. The median common channel length on 3D CT cloacagram was 24.5 mm (range 9-48 mm) and the median urethral length was 15.5 mm (range 13-24 mm). The surgical approach involved a combined abdominoperineal approach in three patients and posterior sagittal anorectal vaginal urethral plasty in one patient. Two patients were awaiting surgical reconstruction at the time of publication.

Conclusions: Our implementation of 3D cloacagram has facilitated precise measurements of both the urethra and common channel lengths, two key factors in formulating surgical strategies for cloacal reconstruction. Moreover, this technique has markedly improved our capacity for surgical planning contributing to colorectal, gynecological, and urological perspectives.

背景:泄殖腔畸形是女性最罕见、最复杂的先天性肛门直肠畸形,其特点是泌尿、妇科和肠道系统汇聚在一个共同通道内。三维计算机断层扫描重建(3D CT 泄殖腔造影)已成为解剖评估和术前规划的重要方法:评估我们使用三维 CT 泄殖腔造影的经验和结果:该回顾性病例系列包括2019-2023年期间在一家机构接受术前三维CT泄殖腔造影的所有泄殖腔畸形患者。收集的数据包括患者特征、三维 CT 泄殖腔造影的时间、三维 CT 泄殖腔造影的结果、与内镜结果的比较、手术过程和术后结果:本研究共纳入六名泄殖腔畸形患者,其中包括两名后泄殖腔患者。三维CT泄殖腔造影显示的总通道中位长度为24.5毫米(范围9-48毫米),尿道中位长度为15.5毫米(范围13-24毫米)。三名患者采用腹会阴联合入路手术,一名患者采用后矢状肛门阴道尿道成形术。在发表文章时,有两名患者正在等待手术重建:我们采用的三维泄殖腔造影有助于精确测量尿道和共同通道的长度,这是制定泄殖腔重建手术策略的两个关键因素。此外,这项技术还显著提高了我们的手术规划能力,有助于从结肠直肠、妇科和泌尿科的角度进行手术规划。
{"title":"Introducing Cloacagram in Israel: Advancing Anatomical Assessment and Surgical Planning for Cloacal Malformations.","authors":"Maya Paran, Osnat Konen, Tal May, Moussa Totah, Michael Levinson, Michael Segal, Dragan Kravarusic, Inbal Samuk","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Cloacal malformation represents the rarest and most complex congenital anorectal malformation in females and is characterized by the convergence of urinary, gynecological, and intestinal systems within a single common channel. Three-dimensional computed tomography reconstruction (3D CT cloacagram) has emerged as a valuable method for anatomical assessment and preoperative planning.</p><p><strong>Objectives: </strong>To evaluate our experience with 3D CT cloacagram and assess its results.</p><p><strong>Methods: </strong>This retrospective case series included all patients with cloacal malformation who underwent preoperative 3D CT cloacagram at a single institution during 2019-2023. Collected data included patient characteristics, timing of the 3D CT cloacagram, results of the 3D CT cloacagram, comparison with endoscopic results, surgical procedures, and postoperative outcome.</p><p><strong>Results: </strong>Six patients with cloacal malformation were included in this study, including two with posterior cloaca. The median common channel length on 3D CT cloacagram was 24.5 mm (range 9-48 mm) and the median urethral length was 15.5 mm (range 13-24 mm). The surgical approach involved a combined abdominoperineal approach in three patients and posterior sagittal anorectal vaginal urethral plasty in one patient. Two patients were awaiting surgical reconstruction at the time of publication.</p><p><strong>Conclusions: </strong>Our implementation of 3D cloacagram has facilitated precise measurements of both the urethra and common channel lengths, two key factors in formulating surgical strategies for cloacal reconstruction. Moreover, this technique has markedly improved our capacity for surgical planning contributing to colorectal, gynecological, and urological perspectives.</p>","PeriodicalId":50268,"journal":{"name":"Israel Medical Association Journal","volume":"26 9","pages":"551-554"},"PeriodicalIF":1.8,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142479619","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Kidney Transplantation in a Patient with Scleroderma. 硬皮病患者的肾移植手术
IF 1.8 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-10-01
Lior Bear, Nancy Agmon Levine, Ronen Ghinea, Tammy Hod, Ido Nachmany, Eytan Mor

Background: Kidney involvement in systemic sclerosis (SSc) is common with altered kidney function present in approximately half of the patients [1]. Scleroderma renal crisis (SRC), the most severe kidney manifestation, occurs in about 20% of patients with this autoimmune disorder [1]. SRC mainly affects patients with the diffuse cutaneous systemic sclerosis (dcSSc) subtype of the disease, and particularly in those who are seropositive to anti RNA polymerase III antibodies [2]. In recent years, the prevalence of SRC has decreased following the initiation of medication therapy with angiotensin-converting-enzyme inhibitors (ACE-i). Previously, SRC mortality rates were as high as 78%. Contemporary studies in the post-ACE-i era suggest lower rates, with mortality rate ranging from 30% to 36% [3]. Nevertheless, progression to end-stage renal disease (ESRD) is evident and may require renal replacement therapies (RRTs). While renal transplant rates in SSc have increased, they constitute a small proportion of SSc-SRC patients (3-8%) and SSc-ESRD patients (4-17%).

背景:系统性硬化症(SSc)的肾脏受累很常见,约半数患者会出现肾功能改变[1]。硬皮病肾危象(SRC)是最严重的肾脏表现,约有20%的自身免疫性疾病患者会出现SRC[1]。SRC主要影响弥漫性皮肤系统性硬化症(dcSSc)亚型患者,尤其是抗RNA聚合酶III抗体血清阳性的患者[2]。近年来,在开始使用血管紧张素转换酶抑制剂(ACE-i)进行药物治疗后,SRC 的发病率有所下降。在此之前,SRC 的死亡率高达 78%。后 ACE-i 时代的当代研究表明死亡率较低,为 30% 至 36% [3]。然而,发展到终末期肾病(ESRD)是显而易见的,可能需要肾脏替代疗法(RRTs)。虽然 SSc 的肾移植率有所上升,但在 SSc-SRC 患者(3-8%)和 SSc-ESRD 患者(4-17%)中所占比例很小。
{"title":"Kidney Transplantation in a Patient with Scleroderma.","authors":"Lior Bear, Nancy Agmon Levine, Ronen Ghinea, Tammy Hod, Ido Nachmany, Eytan Mor","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Kidney involvement in systemic sclerosis (SSc) is common with altered kidney function present in approximately half of the patients [1]. Scleroderma renal crisis (SRC), the most severe kidney manifestation, occurs in about 20% of patients with this autoimmune disorder [1]. SRC mainly affects patients with the diffuse cutaneous systemic sclerosis (dcSSc) subtype of the disease, and particularly in those who are seropositive to anti RNA polymerase III antibodies [2]. In recent years, the prevalence of SRC has decreased following the initiation of medication therapy with angiotensin-converting-enzyme inhibitors (ACE-i). Previously, SRC mortality rates were as high as 78%. Contemporary studies in the post-ACE-i era suggest lower rates, with mortality rate ranging from 30% to 36% [3]. Nevertheless, progression to end-stage renal disease (ESRD) is evident and may require renal replacement therapies (RRTs). While renal transplant rates in SSc have increased, they constitute a small proportion of SSc-SRC patients (3-8%) and SSc-ESRD patients (4-17%).</p>","PeriodicalId":50268,"journal":{"name":"Israel Medical Association Journal","volume":"26 9","pages":"593-595"},"PeriodicalIF":1.8,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142479621","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Economic Burden and Clinical Outcomes of Extracorporeal Membrane Oxygenation in Patients with Coronavirus Disease 2019 at the Tel Aviv Medical Center. 特拉维夫医疗中心 2019 年冠状病毒病患者体外膜氧合的经济负担和临床结果。
IF 1.8 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-10-01
Yael Lichter, Amir Gal Oz, Uri Carmi, Asaph Nini, Dekel Stavi, Noam Goder

Background: The coronavirus disease 2019 (COVID-19) pandemic posed significant challenges to healthcare systems worldwide, including a surge in the use of extracorporeal membrane oxygenation (ECMO).

Objectives: To compare outcomes and costs of COVID-19 and non-COVID-19 adult patients treated with ECMO in the intensive care unit (ICU) at Tel Aviv Sourasky Medical Center.

Methods: We conducted a retrospective study. Clinical outcomes, ECMO duration, ICU and hospital length of stay (LOS), and healthcare costs were examined and compared between the two groups.

Results: A total of 119 patients were treated with ECMO between 2016 and 2023; 56 (47.1%) diagnosed with COVID-19. The study found no significant difference in mortality rates between COVID-19 and non-COVID-19 patients. However, COVID-19 patients experienced significantly longer ECMO durations and ICU LOS. Hospitalization and ECMO operation costs were notably higher for COVID-19 patients, but overall admission costs were lower compared to non-COVID-19 patients, with cost of surgical interventions, consultations and imaging contributing to the price gap.

Conclusions: Despite longer durations of ECMO and LOS, the economic burden of ECMO in COVID-19 patients was significantly lower than non-COVID-19 patients. Strict patient selection should be utilized, a fortiori during times of surge-capacity.

背景:2019 年冠状病毒病(COVID-19)大流行给全球医疗系统带来了重大挑战,包括体外膜肺氧合(ECMO)的使用激增:比较特拉维夫苏拉斯基医疗中心重症监护室(ICU)接受 ECMO 治疗的 COVID-19 和非 COVID-19 成年患者的治疗效果和费用:我们进行了一项回顾性研究。方法: 我们进行了一项回顾性研究,对两组患者的临床结果、ECMO 持续时间、重症监护室和住院时间(LOS)以及医疗费用进行了研究和比较:2016年至2023年间,共有119名患者接受了ECMO治疗,其中56人(47.1%)确诊为COVID-19。研究发现,COVID-19 和非 COVID-19 患者的死亡率无明显差异。然而,COVID-19 患者的 ECMO 持续时间和重症监护室 LOS 明显更长。COVID-19患者的住院和ECMO手术费用明显较高,但与非COVID-19患者相比,总体入院费用较低,手术干预、会诊和成像费用造成了价格差距:结论:尽管 ECMO 和 LOS 的持续时间较长,但 COVID-19 患者的 ECMO 经济负担明显低于非 COVID-19 患者。在容量激增时,更应严格选择患者。
{"title":"The Economic Burden and Clinical Outcomes of Extracorporeal Membrane Oxygenation in Patients with Coronavirus Disease 2019 at the Tel Aviv Medical Center.","authors":"Yael Lichter, Amir Gal Oz, Uri Carmi, Asaph Nini, Dekel Stavi, Noam Goder","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>The coronavirus disease 2019 (COVID-19) pandemic posed significant challenges to healthcare systems worldwide, including a surge in the use of extracorporeal membrane oxygenation (ECMO).</p><p><strong>Objectives: </strong>To compare outcomes and costs of COVID-19 and non-COVID-19 adult patients treated with ECMO in the intensive care unit (ICU) at Tel Aviv Sourasky Medical Center.</p><p><strong>Methods: </strong>We conducted a retrospective study. Clinical outcomes, ECMO duration, ICU and hospital length of stay (LOS), and healthcare costs were examined and compared between the two groups.</p><p><strong>Results: </strong>A total of 119 patients were treated with ECMO between 2016 and 2023; 56 (47.1%) diagnosed with COVID-19. The study found no significant difference in mortality rates between COVID-19 and non-COVID-19 patients. However, COVID-19 patients experienced significantly longer ECMO durations and ICU LOS. Hospitalization and ECMO operation costs were notably higher for COVID-19 patients, but overall admission costs were lower compared to non-COVID-19 patients, with cost of surgical interventions, consultations and imaging contributing to the price gap.</p><p><strong>Conclusions: </strong>Despite longer durations of ECMO and LOS, the economic burden of ECMO in COVID-19 patients was significantly lower than non-COVID-19 patients. Strict patient selection should be utilized, a fortiori during times of surge-capacity.</p>","PeriodicalId":50268,"journal":{"name":"Israel Medical Association Journal","volume":"26 9","pages":"540-545"},"PeriodicalIF":1.8,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142479626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Preliminary Assessment of Galectin-3 Expression in Serum and Follicular Fluid: Implications for Predicting In Vitro Fertilization Outcomes. 血清和卵泡液中 Galectin-3 表达的初步评估:预测体外受精结果的意义
IF 1.8 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-10-01
Gili Kroitoro Man-El, Amir Wiser, Ishai Heusler, Sydney Benchetrit, Netanella Miller, Tal Biron-Shental, Tali Zitman-Gal, Einat Haikin Herzberger

Background: Galactin-3 has been found to be involved in oocyte maturation, folliculogenesis, implantation, and placentation. The expression of Galactin-3 in the endometrium of women who have successfully undergone in vitro fertilization (IVF) has been suggested as a potential biomarker for predicting successful embryo implantation.

Objectives: To evaluate the expression of Galactin-3 in the sera and follicular fluid of women during IVF cycles.

Methods: This prospective research included 21 women undergoing IVF treatments. Blood samples were taken at four points: day 2 before starting stimulation, trigger day, day of oocyte retrieval, and day of the β-human chorionic gonadotropin level test. In addition, follicular fluid samples were taken on the day of oocyte retrieval. Galactin-3 protein levels were measured in serum and follicular fluid using enzyme-linked immunosorbent assay.

Results: Galactin-3 levels on the stimulation day were positively correlated to estradiol levels on the day of the trigger (0.59, P = 0.02). Among women who achieved pregnancy compared to those who did not, Galectin-3 serum levels were higher on the day of the trigger (17.93 ± 4.35 ng/ml vs. 11.01 ± 3.73 ng/ml, P = 0.015).

Conclusions: These findings may imply a potential role of Galectin-3 on the success of IVF treatments, underscoring the potential importance of inflammatory processes in fertility.

背景:研究发现,Galactin-3参与卵母细胞成熟、卵泡生成、着床和胎盘植入。成功接受体外受精(IVF)的妇女的子宫内膜中 Galactin-3 的表达被认为是预测胚胎成功着床的潜在生物标志物:评估体外受精周期中妇女血清和卵泡液中半乳糖苷-3的表达:这项前瞻性研究包括21名接受试管婴儿治疗的女性。在四个时间点采集血样:开始刺激前第 2 天、触发日、取卵日和β-人绒毛膜促性腺激素水平检测日。此外,还在取卵当天采集了卵泡液样本。使用酶联免疫吸附法测定血清和卵泡液中半乳糖苷-3蛋白水平:结果:刺激日的半乳糖苷-3 水平与触发日的雌二醇水平呈正相关(0.59,P = 0.02)。与未怀孕的女性相比,促排卵当天的 Galectin-3 血清水平更高(17.93 ± 4.35 ng/ml vs. 11.01 ± 3.73 ng/ml,P = 0.015):这些发现可能意味着Galectin-3对试管婴儿治疗的成功有潜在作用,强调了炎症过程在生育中的潜在重要性。
{"title":"Preliminary Assessment of Galectin-3 Expression in Serum and Follicular Fluid: Implications for Predicting In Vitro Fertilization Outcomes.","authors":"Gili Kroitoro Man-El, Amir Wiser, Ishai Heusler, Sydney Benchetrit, Netanella Miller, Tal Biron-Shental, Tali Zitman-Gal, Einat Haikin Herzberger","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Galactin-3 has been found to be involved in oocyte maturation, folliculogenesis, implantation, and placentation. The expression of Galactin-3 in the endometrium of women who have successfully undergone in vitro fertilization (IVF) has been suggested as a potential biomarker for predicting successful embryo implantation.</p><p><strong>Objectives: </strong>To evaluate the expression of Galactin-3 in the sera and follicular fluid of women during IVF cycles.</p><p><strong>Methods: </strong>This prospective research included 21 women undergoing IVF treatments. Blood samples were taken at four points: day 2 before starting stimulation, trigger day, day of oocyte retrieval, and day of the β-human chorionic gonadotropin level test. In addition, follicular fluid samples were taken on the day of oocyte retrieval. Galactin-3 protein levels were measured in serum and follicular fluid using enzyme-linked immunosorbent assay.</p><p><strong>Results: </strong>Galactin-3 levels on the stimulation day were positively correlated to estradiol levels on the day of the trigger (0.59, P = 0.02). Among women who achieved pregnancy compared to those who did not, Galectin-3 serum levels were higher on the day of the trigger (17.93 ± 4.35 ng/ml vs. 11.01 ± 3.73 ng/ml, P = 0.015).</p><p><strong>Conclusions: </strong>These findings may imply a potential role of Galectin-3 on the success of IVF treatments, underscoring the potential importance of inflammatory processes in fertility.</p>","PeriodicalId":50268,"journal":{"name":"Israel Medical Association Journal","volume":"26 9","pages":"560-565"},"PeriodicalIF":1.8,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142479623","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Immunomodulation Enhancing Bone Synthesis: A Concept Emerging from One Clinical Case. 免疫调节促进骨合成:从一个临床病例中得出的概念
IF 1.8 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-10-01
George M Weisz, Marina-Portia Anthony, Michael Huang
{"title":"Immunomodulation Enhancing Bone Synthesis: A Concept Emerging from One Clinical Case.","authors":"George M Weisz, Marina-Portia Anthony, Michael Huang","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":50268,"journal":{"name":"Israel Medical Association Journal","volume":"26 9","pages":"537-539"},"PeriodicalIF":1.8,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142479618","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Israel Medical Association Journal
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1